Cytos Biotechnology AG (SWF:CYTN) will release the third quarter earnings for 2009 on Thursday, October 22. For more information, please visit www.cytos.com/?id=947.
Get Rich Penny Stocks is a leading financial publication that is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Cytos Biotechnology AG (Cytos) is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer’s disease. They are designed to instruct the patient’s immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. As of December 31, 2008, the Company had three subsidiaries: Cytos Biotherapeutics Ltd, Mavena AG in liquidation and Proteome Therapeutics GmbH, which was non-operative.
Sign up for the Free GetRichPennyStocks Newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
GetRichPennyStocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that could be on the brink of a breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
